POST Online Media Lite Edition



 

Roche acquires Ariosa Diagnostics

Staff writer |
Roche announced the acquisition of Ariosa Diagnostics, a privately-held company based in San Jose, California.

Article continues below






Ariosa is a molecular diagnostics testing service provider that provides a highly targeted and accurate non-invasive prenatal testing (NIPT) service through their CLIA laboratory using cell-free DNA (cfDNA) technology.

Ariosa’s proprietary Harmony Prenatal Test is a blood test that is performed as early as 10 weeks into pregnancy. By evaluating fetal cfDNA found in maternal blood, the test is designed to assess the risk of Down syndrome and other genetic abnormalities.

Specifically, the test assesses the risk of trisomies 13, 18, and 21, which are indicative of an extra chromosome in the fetus that can lead to severe genetic conditions.

The HarmonyTM Prenatal Test has been validated to CLIA requirements by a robust clinical data set and supported by clinical studies in more than 22,000 women of all ages and risk categories.

There are more than 200 million pregnancies annually worldwide1 and prenatal screening for Down syndrome has become common practice, in many countries. Conventional screening tests return false positive results up to 5%2 of the time, compared to the HarmonyTM Prenatal Test which has a false positive result of less than 0.1%3.

The closing of the transaction is expected to take place in December, 2014.


What to read next

Roche to invest 450 million Swiss Francs in China
Roche buys superbug diagnostics firm for up to $425 million
Roche Group Q1 group sales up 5%